ArticleHeliyon2024
Association between history of viral infections and melanoma mortality.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral infections (VIs) have been linked to T-cell exhaustion, a state that impacts the immune system's ability to mount an effective anti-tumor response. This immunosuppressive effect may potentially worsen outcomes in melanoma patients. This study investigates the relationship between a history of VIs and melanoma-specific mortality, with the goal of understanding whether prior history of Vis contribute to an increased risk of mortality in melanoma patients. Materials and methods: A retrospective review of patients in the Utah Population Database (1997-2020) was done. There were 17,754 eligible melanoma patients, with 2286 also having a history of viral infections. Multivariable Cox proportional hazard models were used to assess the effect of VI on melanoma-specific mortality. Results: History of VI was associated with a higher risk of melanoma-specific mortality (HR = 1.33, 95 % CI: 1.07-1.65, P = 0.01). No differences were observed in mortality among patients undergoing surgery and adjuvant immunotherapy. Conclusions: A history of viral infections was associated with higher melanoma-specific mortality. The mechanism of this association and relationship with different types of viral infections and duration of infections remain to be elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.